DJIA 16,204.97 -211.61 -1.29%
NASDAQ 4,363.14 -146.42 -3.25%
S&P 500 1,880.05 -35.40 -1.85%
market minute promo


24.12 -0.07 (-0.29%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

TKPYY $24.12 -0.29%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.90
Previous Close $24.19
Daily Range $23.90 - $24.31
52-Week Range $21.51 - $27.52
Market Cap $38.1B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.6%)
Volume 16,832
Average Daily Volume 29,022
Current FY EPS $0.37





News & Commentary Rss Feed

Blame This for Orexigen Therapeutics, Inc.'s Mind-Numbingly Bad 2015

It was expected to be Orexigen's greatest selling point, but this miscue turned into a nightmare for the company's weight-control management drug Contrave.

6 Billion Reasons This Biotech Is a Buy

The revenue potential of this company's lead product candidate looks astounding.

3 Biotech Stocks We're Ready to Sell

Our contributors think its time to head for the exits on these three biotechs.

Why Orexigen Therapeutics Inc Stock Fell 18% in July

Tension between Orexigen and its marketing partner Takeda Pharmaceuticals continues to build after reports of a recall on obesity medication Contrave surface.

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

Why It's Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

5 Largest Markets for Pharmaceuticals

The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.

Why ImmunoGen Inc. Shares Tumbled Today

After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

Forget About Ebola Stocks and Invest in This Instead

Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.

See More TKPYY News...